Table 1 Study population description
| Â | Controls (n = 1057) | Gleason 6 PC (n = 402) | Gleason 7 PC (n = 272) | Gleason 8-10 PC (n = 135) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Median | 25th-75th | Median | 25th-75th | Median | 25th-75th | Median | 25th-75th | p* |
Age (years) | 64.0 | 58.0-70.0 | 64.5 | 59.0-70.0 | 66.0 | 61.0-72.0 | 69.0 | 64.0-75.0 | < 0.01 |
PSA (ng/ml) | 5.0 | 4.0-6.8 | 5.0 | 4.2-6.7 | 6.0 | 4.6-8.4 | 8.0 | 5.5-16.4 | < 0.01 |
Prostate Volume (ml) | 45.1 | 33.3-62.8 | 37.7 | 28.2-53.0 | 33.0 | 25.8-45.0 | 35.6 | 26.1-49.6 | < 0.01 |
| Â | n | % | n | % | n | % | n | % | Â |
Non-white ethnicity | 103 | 9.7% | 50 | 12.4% | 38 | 13.9% | 14 | 10.3% | 0.17 |
Family History PC | 215 | 20.3% | 112 | 27.9% | 58 | 21.3% | 17 | 12.5% | < 0.01 |
Diabetes Tx | 149 | 14.1% | 50 | 12.4% | 40 | 14.7% | 22 | 16.3% | 0.68 |
CVD Tx | 591 | 55.9% | 244 | 60.7% | 171 | 62.9% | 77 | 57.0% | 0.12 |
BPH Tx | 210 | 19.9% | 74 | 18.4% | 44 | 16.2% | 16 | 11.9% | 0.10 |
Hyperlipidemia Tx | 436 | 41.3% | 180 | 44.8% | 121 | 55.5% | 60 | 44.4% | 0.54 |